STOCK TITAN
  1. Home
  2. Sec-filings
  3. KROS
  4. [8-K] Keros Therapeutics, Inc. Reports Material Event

Keros Therapeutics (NASDAQ: KROS) names interim finance and accounting head

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Keros Therapeutics, Inc. disclosed that Chief Financial Officer Keith Regnante resigned, effective August 3, 2026, to pursue other opportunities. The Board appointed Corporate Controller and Vice President, Finance, Annita Tanini, age 55, as interim principal financial officer and principal accounting officer effective August 4, 2026, while a search for a new CFO is underway.

Under a new executive employment agreement, Ms. Tanini will receive an annual base salary of $302,300 and be eligible for an annual cash bonus targeted at 30% of base salary. If terminated without cause or she resigns for good reason, she may receive six months of base salary and up to six months of COBRA premium payments, subject to a release. Mr. Regnante will receive accrued salary and standard benefits under his existing employment agreement and is not entitled to additional severance beyond amounts required by law.

Positive

  • None.

Negative

  • None.

Filing Explained

The filing states that the full Tanini employment agreement is not included in this 8-K and is expected to be filed as an exhibit to the company’s Form 10-Q for the quarter ended June 30, 2026, providing the stated path to review its complete terms.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
CFO separation date August 3, 2026 Effective date of Keith Regnante’s resignation as Chief Financial Officer
Interim appointment effective date August 4, 2026 Date Annita Tanini becomes interim principal financial and accounting officer
Annita Tanini base salary $302,300 per year Annual base salary under the Tanini Employment Agreement
Target bonus percentage 30% of annual base salary Target annual cash bonus opportunity for Ms. Tanini
Severance salary duration Six months Duration of base-salary severance for certain terminations of Ms. Tanini
COBRA premium support period Up to six months Maximum period Keros may pay COBRA premiums for Ms. Tanini and dependents
Annita Tanini age 55 Age of the interim principal financial and accounting officer
principal financial officer financial
"appointed ... as the Company’s interim principal financial officer and principal accounting officer"
The principal financial officer is the senior executive who runs a company's financial operations: preparing and certifying financial reports, managing accounting controls, budgets and cash flow, and advising on financial strategy. Investors care about this role because its competence affects how trustworthy the company’s numbers are, how well it manages risk and capital needs, and the credibility of forecasts—like the chief navigator steering a firm's financial course.
good reason financial
"termination ... without cause or Ms. Tanini's resignation for good reason"
COBRA premiums financial
"payment by the Company of COBRA premiums for Ms. Tanini and her eligible dependents"
emerging growth company regulatory
"Rule 12b-2 of the Securities Exchange Act of 1934 ... Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Regulation S-K regulatory
"would require disclosure under Item 401(d) of Regulation S-K"
A set of U.S. Securities and Exchange Commission rules that tell public companies which narrative and qualitative details must be disclosed in filings, such as risk factors, management discussion, executive pay, legal proceedings and business description. Think of it as a standardized checklist or blueprint that ensures investors get the same types of background information from every company so they can compare risks, management quality and strategy before making investment decisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What executive change did Keros Therapeutics (KROS) announce?
Keros Therapeutics announced that CFO Keith Regnante resigned effective August 3, 2026. Annita Tanini, previously Corporate Controller and Vice President, Finance, will serve as interim principal financial officer and principal accounting officer starting August 4, 2026.

Who is Annita Tanini and what is her new role at KROS?
Annita Tanini, age 55, has held finance leadership roles at Keros since May 2019. She has been appointed interim principal financial officer and principal accounting officer, after serving as Corporate Controller and Vice President, Finance.

What compensation will Keros Therapeutics (KROS) pay Annita Tanini?
Under her executive employment agreement, Annita Tanini will receive an annual base salary of $302,300 and is eligible for an annual cash bonus targeted at 30% of her base salary, subject to company performance and applicable plan terms.

What severance protections does Annita Tanini have at Keros Therapeutics (KROS)?
If Keros terminates her without cause or she resigns for good reason, Ms. Tanini may receive six months of base salary and up to six months of COBRA premiums, contingent on signing and not revoking a release of claims.

What benefits will departing CFO Keith Regnante receive from Keros Therapeutics (KROS)?
Keith Regnante will receive accrued base salary through August 3, 2026, reimbursement of properly incurred business expenses, and the right to elect COBRA health coverage at his own expense. He is not entitled to additional severance beyond amounts required by law.

Did Keith Regnante’s resignation from Keros Therapeutics (KROS) involve any disagreement?
The company states that Mr. Regnante’s resignation was voluntary and not due to any disagreement regarding accounting practices, financial statements, internal control over financial reporting, operations, policies or practices at Keros Therapeutics.
0001664710FALSE00016647102026-07-172026-07-17

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K 
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 17, 2026
 
 
Keros Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
 
 
 
Delaware 001-39264 81-1173868
(state or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(I.R.S. Employer
Identification No.)
1050 Waltham Street, Suite 302
Lexington, Massachusetts
 02421
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (617) 314-6297
 
Not applicable
(Former name or former address, if changed since last report.)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 
 
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 


 
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class 
Trading
Symbol
 
Name of each exchange
on which registered
Common Stock, $0.0001 par value per share KROS The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Executive Transition

On July 17, 2026, Keith Regnante resigned from his role as Chief Financial Officer of Keros Therapeutics, Inc. (the “Company”), effective August 3, 2026 (the “Separation Date”), to pursue other opportunities. In connection with Mr. Regnante’s departure, the Company’s Board of Directors (the “Board”) appointed Annita Tanini, the Company’s Corporate Controller and Vice President, Finance, as the Company’s interim principal financial officer and principal accounting officer, effective as of August 4, 2026. Mr. Regnante’s resignation was voluntary and was not the result of any disagreement with the Company on any matter relating to the Company’s accounting practices, financial statements, internal controls over financial reporting, operations, policies or practices. The Company has commenced a search for a new Chief Financial Officer.

Ms. Tanini, age 55, has served in finance leadership roles at the Company since May 2019, most recently as Corporate Controller and Vice President, Finance. From December 2015 to April 2017, she was the Vice President of Finance of Avedro, Inc., a commercial-stage ophthalmic medical technology company. Prior to that, Ms. Tanini was Senior Vice President of Finance of Fiksu, Inc., a mobile advertising and marketing technology company from March 2014 to November 2015. Previously, Ms. Tanini held Vice President of Finance roles at VideoIQ, Inc., MediaFriends, Inc., Jingle Networks Inc. and Arnold Worldwide LLC. Ms. Tanini holds a B.S. in finance and accounting, and an M.B.A. from the University of Massachusetts Lowell.

Ms. Tanini’s Compensation Arrangements

In connection with Ms. Tanini’s appointment, the Company and Ms. Tanini entered into an executive employment agreement, effective as of August 4, 2026 (the “Tanini Employment Agreement”). Under the Tanini Employment Agreement, Ms. Tanini will receive an annual base salary of $302,300 and will be eligible for an annual cash bonus with a target amount equal to 30% of her annual base salary. In the event of a termination of Ms. Tanini’s employment by the Company without cause or Ms. Tanini's resignation for good reason (as defined in the Tanini Employment Agreement), Ms. Tanini will be eligible to receive (i) six months of her then-current base salary, paid in installments in accordance with the Company's normal payroll practices, and (ii) payment by the Company of COBRA premiums for Ms. Tanini and her eligible dependents for up to six months, in each case subject to her execution and non-revocation of a general release of claims in favor of the Company.

There are no arrangements or understandings between Ms. Tanini and any other persons pursuant to which Ms. Tanini was selected as the Company’s interim principal financial officer and principal accounting officer. There is no family relationship between Ms. Tanini and any other person that would require disclosure under Item 401(d) of Regulation S-K. Ms. Tanini is also not a party to any transactions that would require disclosure under Item 404(a) of Regulation S-K.

Mr. Regnante’s Separation Benefits

Mr. Regnante’s separation entitlements are governed by his employment agreement, dated as of March 31, 2020, as amended on January 1, 2022 (the “Regnante Employment Agreement”). Under the Regnante Employment Agreement, in connection with his departure, Mr. Regnante is entitled to receive: (i) payment of base salary accrued through and including the Separation Date; (ii) reimbursement of business expenses properly incurred but not yet reimbursed as of the Separation Date, in accordance with the Company’s applicable expense reimbursement policies; and (iii) the right to elect continuation coverage under the Company’s group health plans pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended, at Mr. Regnante’s sole expense, to the extent permitted by and subject to applicable law. Mr. Regnante is not entitled to any additional severance payments, compensation or benefits from the Company in connection with his departure, except as may be required by applicable law.

The foregoing descriptions of the Tanini Employment Agreement and the Regnante Employment Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of such agreements. A copy of the Tanini Employment Agreement is expected to be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending June 30, 2026, and upon such filing will be incorporated herein by reference. The Regnante Employment Agreement was previously filed as Exhibit 10.17 to the Company’s Registration Statement on Form S-1/A filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2020, and the First Amendment thereto was previously filed as Exhibit 10.21 to the Company’s Annual Report on Form 10-K filed with the SEC on March 9, 2022, each of which is incorporated herein by reference.


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
KEROS THERAPEUTICS, INC.
By: /s/ Jasbir Seehra
 
Jasbir Seehra, Ph.D.
Chief Executive Officer
Dated: July 22, 2026

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Other Documents